SecBot SecBot
SECBOTREPLAY Home › Report › ERAS

ERAS · Erasca reported encouraging preliminary Phase 1 data for ERAS-0015, its…

Erasca, Inc. · PRESS-RELEASE filed Jul 13, 2026 at 16:01 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Jul 13, 2026 at 16:01 ET

Erasca reported encouraging preliminary Phase 1 data for ERAS-0015, its pan-RAS molecular glue, showing a 57% unconfirmed overall response rate (uORR) at 8 weeks in 2L+ KRAS G12X pancreatic cancer at the 32 mg QD recommended dose. The company outlined accelerated development plans including a potentially registration-enabling trial in lung cancer in H1 2027 and a Phase 3 pancreatic cancer trial in 2027, which for an early-stage biotech is a significant positive catalyst.

  • 57% uORR8wk in 2L+ KRAS G12X pancreatic cancer at RDE of 32 mg QD (N=7).
  • Median relative dose intensity of 100% at both 24 mg QD and 32 mg QD.
  • No DLTs observed; therapy generally well-tolerated with no discontinuations due to TRAEs.
  • First dose escalation combination cohort of ERAS-0015 (16 mg) with panitumumab cleared without DLTs.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access